clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Fractures, Open D005597 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Cysts D003560 4 associated lipids
Duodenitis D004382 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Jenkins H et al. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. 2017 Clin Drug Investig pmid:27928738
Alba C et al. Antibiotic resistance in Helicobacter pylori. 2017 Curr. Opin. Infect. Dis. pmid:28704226
Mishima E et al. Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. 2017 Intern. Med. pmid:28674358
Sun W et al. Synergistic drug combination effectively blocks Ebola virus infection. 2017 Antiviral Res. pmid:27890675
Shimoyama T et al. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. 2017 Intern. Med. pmid:28674348
Hung IFN et al. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. 2017 Chest pmid:27884765
Ustundag GH et al. The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. 2017 Can J Gastroenterol Hepatol pmid:28656129
Peng X et al. Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. 2017 Int J Med Sci pmid:28638276
Ozturk O et al. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. 2017 Arab J Gastroenterol pmid:28601610
Aguilera-Correa JJ et al. Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. 2017 Diagn. Microbiol. Infect. Dis. pmid:27863951
Alirezaei A et al. Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. 2017 Iran J Kidney Dis pmid:28575885
Katayama Y et al. Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. 2017 Life Sci. pmid:27825902
Cosme A et al. Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. 2017 World J. Gastroenterol. pmid:28566898
Moj D et al. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. 2017 AAPS J pmid:27822600
Angol DC et al. from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. 2017 Biomed Res Int pmid:28555193
Akpinar Z et al. Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. 2017 Arab J Gastroenterol pmid:28532623
Beckman E et al. A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. 2017 J. Clin. Microbiol. pmid:28515219
Kajihara Y et al. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. 2017 Scand. J. Gastroenterol. pmid:27806639
Yan J et al. Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital. 2017 Eur Arch Otorhinolaryngol pmid:28508178
Shaulov A et al. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. 2017 Am. J. Hematol. pmid:27804150
DaCosta A et al. Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. 2017 J. Cyst. Fibros. pmid:28495380
Sharifi R et al. Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori. 2017 Lipids pmid:28493185
Reddy AB and Reddy ND Development of Multiple-Unit Floating Drug Delivery System of Clarithromycin: Formulation, in vitro Dissolution by Modified Dissolution Apparatus, in vivo Radiographic Studies in Human Volunteers. 2017 Drug Res (Stuttg) pmid:28449156
Ivanová L et al. Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. 2017 Environ. Res. pmid:28183039
Giguère S et al. Antimicrobial Resistance in . 2017 Microbiol Spectr pmid:29052538
Varma MV et al. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. 2017 Clin. Pharmacol. Ther. pmid:27648490
Huet D et al. [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. 2017 Rev Mal Respir pmid:27639948
El Haj C et al. The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? 2017 Med. Microbiol. Immunol. pmid:27639707
Jia L et al. Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. 2017 Bioorg. Med. Chem. Lett. pmid:28711353
Seyama S et al. Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). 2017 J. Antimicrob. Chemother. pmid:27999037
Zerbetto De Palma G et al. Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. 2017 Microb. Drug Resist. pmid:27391421
Giguère S Treatment of Infections Caused by Rhodococcus equi. 2017 Vet. Clin. North Am. Equine Pract. pmid:28161038
Berni E et al. Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. 2017 BMJ Open pmid:28115334
Legendre T et al. [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. 2017 Encephale pmid:27178256
Choi HS et al. Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. 2017 Jpn. J. Infect. Dis. pmid:27169951
Serrano CA et al. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. 2017 J. Pediatr. Gastroenterol. Nutr. pmid:27159208
Yatera K et al. The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. 2017 Respir Investig pmid:29153420
Lee MC et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. 2017 J. Antimicrob. Chemother. pmid:29091186
Takahashi C et al. Morphological study of efficacy of clarithromycin-loaded nanocarriers for treatment of biofilm infection disease. 2017 Med Mol Morphol pmid:27119723
Laidler N Cutaneous infection with paucibacillary treated successfully with a modified antituberculous drug regimen. 2017 BMJ Case Rep pmid:29275384
Lee JS et al. Implication of species change of Nontuberculous Mycobacteria during or after treatment. 2017 BMC Pulm Med pmid:29262802
Ruiter R et al. Helicobacter pylori resistance in the Netherlands: a growing problem? 2017 Neth J Med pmid:29219812
Pastukh N et al. GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. 2017 Helicobacter pmid:29058343
Tognetti L et al. Bullous impetigo during interstitial pneumonitis. 2017 G Ital Dermatol Venereol pmid:29050448
Chen MJ et al. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. 2017 J. Antimicrob. Chemother. pmid:28961996
Kim SY et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. 2017 Helicobacter pmid:28940815
Mukherjee D et al. Vancomycin and Clarithromycin Show Synergy against . 2017 Antimicrob. Agents Chemother. pmid:28923867
Tsay FW et al. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. 2017 Antimicrob. Agents Chemother. pmid:28807915
Oh ES et al. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. 2017 J Clin Pharm Ther pmid:28806472
Kuo YT et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. 2017 Lancet Gastroenterol Hepatol pmid:28781119
Ramas M et al. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. 2017 Gastroenterol Hepatol pmid:28780968
Souto Filho JTD et al. Long-term complete remission of primary gastric plasmacytoma following endoscopic resection. 2017 Ann. Hematol. pmid:28315923
Antonakos N et al. Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. 2017 Crit Care pmid:28274246
Koratala A et al. Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. 2017 Blood Purif. pmid:28268216
Lin CM et al. Is ionizing radiation a risk factor to diffuse panbronchiolitis? 2017 QJM pmid:28069906
Zhang D et al. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. 2017 Medicine (Baltimore) pmid:28796053
Fraser AG Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. 2017 Aliment. Pharmacol. Ther. pmid:28776748
Jung YS et al. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28776746
Makihara K et al. Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. 2017 Cancer Chemother. Pharmacol. pmid:28711984
Tanabe H et al. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. 2017 Dig. Dis. Sci. pmid:28664410
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Sue S et al. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. 2017 Intern. Med. pmid:28566587
Hu Y et al. Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance. 2017 Front Cell Infect Microbiol pmid:28529929
Jeong SH et al. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. 2017 Int. J. Infect. Dis. pmid:28522316
Kishida D et al. Intractable Cutaneous Nontuberculous Mycobacteriosis (Mycobacterium abscessus) during Treatment for Systemic Lupus Erythematosus. 2017 Intern. Med. pmid:28502947
Jung YS et al. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. 2017 Aliment. Pharmacol. Ther. pmid:28497487
Sharman MJ et al. Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. 2017 Vet. Immunol. Immunopathol. pmid:28494926
O'Brien CR et al. Feline leprosy due to Candidatus 'Mycobacterium tarwinense':Further clinical and molecular characterisation of 15 previously reported cases and an additional 27 cases 2017 J. Feline Med. Surg. pmid:28438086
Komiya K et al. Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. 2017 Respir. Res. pmid:28219384
Sakurai K et al. Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 World J. Gastroenterol. pmid:28216974
Awan S et al. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. 2017 Lung Cancer pmid:28213005
Su J et al. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. 2017 Medicine (Baltimore) pmid:28207505
Branquinho D et al. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? 2017 BMC Gastroenterol pmid:28202013
Inukai K et al. Effect of gel formation on the dissolution behavior of clarithromycin tablets. 2017 Int J Pharm pmid:28196716
Miftahussurur M et al. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. 2017 Am. J. Trop. Med. Hyg. pmid:28193745
Zhang Z et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. 2017 Int. J. Antimicrob. Agents pmid:28188830
Kristin F et al. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. 2017 Eur J Pharm Sci pmid:28179133
Chen D et al. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. 2017 Antimicrob. Agents Chemother. pmid:28167563
Olesen JS et al. Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy. 2017 BMJ Case Rep pmid:28137898
Chang JY et al. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. 2017 BMC Gastroenterol pmid:28109257
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Couture G et al. [Second case of serum sickness-like reaction to claritrhomycin]. 2016 Presse Med pmid:27542759
Bugli F et al. In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. 2016 Biotechnol. Prog. pmid:27535356
Abd-Elsalam S et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. 2016 Medicine (Baltimore) pmid:27310977
De Francesco V et al. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication. 2016 J Gastrointestin Liver Dis pmid:27308644
Miyaki A et al. An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility. 2016 Minerva Gastroenterol Dietol pmid:27304198
Kim JS et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. 2016 Gut Liver pmid:27114421
Manniello MD et al. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt. 2016 Eur J Pharm Biopharm pmid:27106605
Fallone CA et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. 2016 Gastroenterology pmid:27102658
Bilgilier C et al. Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. 2016 Ann. Hematol. pmid:27091350
Park JY et al. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. 2016 Dig. Dis. Sci. pmid:26923948
Guirao-Arrabal E et al. Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. 2016 Rev Esp Quimioter pmid:26888341
Trac MH et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. 2016 CMAJ pmid:26903359
Mukai S et al. Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. 2016 Int. J. Oncol. pmid:26718641
Hirama T et al. PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates. 2016 J. Clin. Microbiol. pmid:26739154
Radheshi E et al. Postmortem diagnosis of anaphylaxis in presence of decompositional changes. 2016 J Forensic Leg Med pmid:26735898
Hassan ST et al. In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. 2016 Pharm Biol pmid:26731378
Hollitt A et al. Cat scratch disease of the parotid gland. 2016 Arch. Dis. Child. pmid:26403943
Oh B et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. 2016 Helicobacter pmid:26395781